These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2498 related articles for article (PubMed ID: 7845864)
1. 6-Methylene progesterone is cytotoxic to human cancer cell lines independent of its 5-alpha-reductase activity. Roberson KM; Padilla GM; Schmidt JM; Petrow V; Robertson CN Prostate; 1995 Jan; 26(1):28-34. PubMed ID: 7845864 [TBL] [Abstract][Full Text] [Related]
2. Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro. Robertson CN; Roberson KM; Pinero A; Jaynes JM; Paulson DF World J Urol; 1998; 16(6):405-9. PubMed ID: 9870289 [TBL] [Abstract][Full Text] [Related]
3. A comparison of the effects of castration and 6-methylene progesterone, a 5 alpha-reductase inhibitor, on the rat ventral prostate. Marts SA; Padilla GM; Petrow V Biochem Cell Biol; 1987 Jul; 65(7):626-34. PubMed ID: 3435660 [TBL] [Abstract][Full Text] [Related]
4. Effects of 6-methylene progesterone on growth, morphology, and blood flow of the Dunning R3327 prostatic adenocarcinoma. Damber JE; Bergh A; Daehlin L; Petrow V; Landström M Prostate; 1992; 20(3):187-97. PubMed ID: 1574466 [TBL] [Abstract][Full Text] [Related]
5. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Maria McCrohan A; Morrissey C; O'Keane C; Mulligan N; Watson C; Smith J; Fitzpatrick JM; Watson RW Cancer; 2006 Jun; 106(12):2743-52. PubMed ID: 16703599 [TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. Robertson CN; Roberson KM; Padilla GM; O'Brien ET; Cook JM; Kim CS; Fine RL J Natl Cancer Inst; 1996 Jul; 88(13):908-17. PubMed ID: 8656443 [TBL] [Abstract][Full Text] [Related]
7. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730 [TBL] [Abstract][Full Text] [Related]
8. Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. Bruchovsky N; Rennie PS; Batzold FH; Goldenberg SL; Fletcher T; McLoughlin MG J Clin Endocrinol Metab; 1988 Oct; 67(4):806-16. PubMed ID: 2458378 [TBL] [Abstract][Full Text] [Related]
9. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686 [TBL] [Abstract][Full Text] [Related]
10. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. Theyer G; Schirmböck M; Thalhammer T; Sherwood ER; Baumgartner G; Hamilton G J Urol; 1993 Nov; 150(5 Pt 1):1544-7. PubMed ID: 8105110 [TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750 [TBL] [Abstract][Full Text] [Related]
12. Steroidal antiandrogens and 5alpha-reductase inhibitors. Bratoeff E; Ramírez E; Murillo E; Flores G; Cabeza M Curr Med Chem; 1999 Dec; 6(12):1107-23. PubMed ID: 10519917 [TBL] [Abstract][Full Text] [Related]
13. Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. Sutkowski DM; Audia JE; Goode RL; Hsiao KC; Leibovitch IY; McNulty AM; Neubauer BL Prostate Suppl; 1996; 6():62-6. PubMed ID: 8630232 [TBL] [Abstract][Full Text] [Related]
14. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Bonkhoff H; Stein U; Aumüller G; Remberger K Prostate; 1996 Oct; 29(4):261-7. PubMed ID: 8876709 [TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Lin MF; Kawachi MH; Stallcup MR; Grunberg SM; Lin FF Prostate; 1995 Apr; 26(4):194-204. PubMed ID: 7716084 [TBL] [Abstract][Full Text] [Related]
16. Characterization of ALVA-41 cells, a new human prostatic cancer cell line. Nakhla AM; Rosner W Steroids; 1994 Oct; 59(10):586-9. PubMed ID: 7533340 [TBL] [Abstract][Full Text] [Related]
17. 5 alpha-reductase-catalyzed conversion of testosterone to dihydrotestosterone is increased in prostatic adenocarcinoma cells: suppression by 15-lipoxygenase metabolites of gamma-linolenic and eicosapentaenoic acids. Pham H; Ziboh VA J Steroid Biochem Mol Biol; 2002 Nov; 82(4-5):393-400. PubMed ID: 12589947 [TBL] [Abstract][Full Text] [Related]
18. Approaches to prostatic cancer chemotherapy using the Dunning R3327H prostatic adenocarcinoma. Padilla GM; Petrow V; Marts SA; Mukherji S Prostate; 1985; 6(2):129-43. PubMed ID: 3975175 [TBL] [Abstract][Full Text] [Related]
19. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line. Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094 [TBL] [Abstract][Full Text] [Related]
20. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. de la Taille A; Hayek OR; Buttyan R; Bagiella E; Burchardt M; Katz AE BJU Int; 1999 Nov; 84(7):845-50. PubMed ID: 10532984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]